In the past, women in menopause were brushed aside and told that their symptoms were “just stress” or a “natural part of aging.” Implicit in this message was the expectation that women were to push through this transition and endure its symptoms on their own without support. Now, the pendulum has swung and this midlife transition is finally getting some attention. The problem now is that this newfound medical attention is not always helping as much as it could. Increasingly, women are being treated quickly and sometimes with more intervention than understanding. Patients are arriving at my practice already on treatment plans they do not fully understand. Hormones, supplements, compounded creams, and sometimes newer medications are started within a short window of time. Many are spending hundreds of dollars each month on customized prescriptions or supplements. Some are feeling better, but others are not. More importantly, they are not sure which medication or supplement is helping and which is not.
Let me give you an example of one of my patients. She came to me after being started on multiple therapies within a single month, including estradiol, progesterone, testosterone, and a glucagon-like peptide-1 (GLP-1) medication. She had initially been looking for help with fatigue, weight changes, and poor sleep. By the time I saw her, she could not tell me which medication was meant to address which symptom or whether any of her medications were helping. There had not been enough time to establish a baseline, assess medication response, or even step back and ask whether all of it was necessary in the first place. None of these treatments are inherently inappropriate. In the right context, each can have an important role. However, starting them all at once muddied the opportunity to individualize care, monitor what was working, and make thoughtful adjustments along the way. What she needed was not more intervention. She needed a more deliberate approach.
Hormone therapy is no longer confined to traditional medical settings. It is increasingly available not only through telehealth companies, but also through brick-and-mortar med spas, intravenous (IV) hydration clinics, anti-aging centers, franchise wellness chains, and compounding pharmacy-linked practices. In many of these environments, prescriptions are presented alongside other services, effectively placing medical treatment within a retail-style menu. While this model expands access, it can also shift the focus toward convenience and transactions rather than individualized, longitudinal care. When treatment is delivered this way, the careful attention required for safe and effective menopause management can be lost. Direct-to-consumer telehealth care has helped expand access to women in meaningful ways. Many women are finally being heard, sometimes for the first time. That matters. For patients who have struggled to find knowledgeable clinicians, telehealth can be a lifeline, especially to those in areas of the country with few menopause-society-certified providers. Yet, improved access does not always equate to improved care. Moreover, the diverse presentations of menopause do not lend themselves well to quick, standardized, one-size-fits-all solutions.
Menopause is a complex, highly individualized transition. Hormones play a role, but so do sleep, mental health, metabolic changes, stress, and life context. Good care takes time and often requires iteration and fine-tuning. It rarely follows a standard protocol. Yet, many modern care models are built for efficiency and scale, not necessarily for nuance and individualization. Over the past several years, investment in women’s health has accelerated. Much of this growth has been fueled by venture capital, which tends to prioritize scalability, efficiency, and return on investment. Those forces can expand access, but they also shape how care is delivered. When care is designed to scale quickly, efficiency becomes the priority. Menopause care, however, often requires the opposite, time, thoughtful consideration, and individualized decision-making.
As a result, patients are left trying to sort through a mix of clinical advice, marketing, and incomplete information. Many do not realize what is missing. They do not see the absence of a thorough history, the lack of attention to sleep or mental health, or the missed opportunity to fully understand their symptoms before starting treatment. They assume this is what modern care looks like. It does not have to be this way. Hormone therapy illustrates this tension clearly. The evidence supporting its use in appropriately selected patients is strong. When prescribed thoughtfully, it can be transformative. It is not one-size-fits-all. It requires careful selection, timing, and follow-up. What I am seeing more often is a shift toward simplification. Hormones are often presented as a universal solution rather than one component of a broader, individualized plan.
Good menopause care is intentional and patient-centered. It starts with listening and requires an understanding of symptoms in context, not in isolation. It includes a balanced discussion of treatment options, both pharmaceutical and nonpharmaceutical. It includes transparent discussion about what is supported by evidence and where uncertainty remains. It also evolves over time, adapting to the patient’s changing needs. Most importantly, it is grounded in trust, not transactions. The growing visibility of menopause and its treatment is something to build on. More research, more attention, and better access are needed. However, if that visibility comes with oversimplified care and rapid treatment escalation, we risk replacing one problem with another. Women in midlife are not a protocol to follow or a market to optimize. They are patients navigating a complex and often vulnerable transition. They deserve care that is careful, individualized, and worthy of their trust.
Kari Waddell is a nurse practitioner.
